> Novo Nordisk (NOVOb.CO) will supply Greece with its drugs as normal after authorities proposed a new pricing formula, but could face fines for pulling them off the market, Greece's drug watchdog said. Report
> Barclays raised its rating on AstraZeneca (UK:AZN, AZN) to overweight, saying it believes the company stands a 60 percent to 65 percent chance of victory in the U.S. patent dispute around cholesterol treatment Crestor. Report
> Generic companies hoping to market a cheap copy of GlaxoSmithKline's (GSK.L) best-selling inhaled lung drug Advair might have wait until 2012 before winning a green light from regulators in Europe. Report
> Only 38 percent of European biopharmaceutical companies feel that they have the ability to influence market access stakeholders, according to new research. Report
> GlaxoSmithKline received a second rebuff in as many days from Britain's NICE when the healthcare cost watchdog ruled its platelet-boosting drug Revolade was not worth using on the state health service. Report
> Harbin Pharmaceutical (HPG), the Chinese buyer of Pfizer's swine vaccine unit, is preparing workshops and technicians to take over the production line, the company announced. Report
> A drug commonly used to treat gout may help patients with chronic kidney disease keep their condition in check and reduce the risk of heart problems, Spanish scientists said. Report
> Hospira said that European Union regulators have approved its drug Nivestim as a treatment for certain side effects of chemotherapy. Report
Biotech News
@FierceBiotech: Covance plans 300 hires for Indiana campus. Report | Follow @FierceBiotech
@JohnCFierce: Sharing data on failed Alzheimer's trials makes a lot of sense. It's also cool to see biopharma companies working together. | Follow @JohnCFierce
> Big Pharma coalition will pool data on failed Alzheimer's drugs. Report
> Precision Therapeutics gets $33M to support ChemoFx. Story
> UCB ups stake in oncology partner. Item
> BMS, Pfizer wrap apixaban stroke trial early on positive verdict. Results
> Inotek gathers $18M as it plots PhII trials. News
> FDA panel hands Novartis lopsided endorsement of oral MS therapy. Article
And Finally... Why aren't more patients getting the shingles vaccine? Report